| [1] |
CHEN GD, LAI XQ, KO DS, et al. Comparison of efficacy and safety between rabbit anti-thymocyte globulin and anti-T lymphocyte globulin in kidney transplantation from donation after cardiac death: a retrospective cohort study[J]. Nephrology (Carlton), 2015, 20(8):539-543. DOI: 10.1111/nep.12469.
|
| [2] |
SHISHIDO S, SATOU H, MURAMATSU M, et al. Combination of pulse methylprednisolone infusions with cyclosporine-based immunosuppression is safe and effective to treat recurrent focal segmental glomerulosclerosis after pediatric kidney transplantation[J]. Clin Transplant, 2013, 27(2):E143-E150. DOI: 10.1111/ctr.12079.
|
| [3] |
LAZELLE RA, MCCULLY BH, TERKER AS, et al. Renal deletion of 12 kDa FK506-binding protein attenuates tacrolimus-induced hypertension[J]. J Am Soc Nephrol, 2016, 27(5):1456-1464. DOI: 10.1681/ASN.2015040466.
|
| [4] |
CHUNG BH, KIM KW, YU JH, et al. Decrease of immature B cell and interleukin-10 during early-post-transplant period in renal transplant recipients under tacrolimus based immunosuppression[J]. Transpl Immunol, 2014, 30(4):159-167. DOI: 10.1016/j.trim.2014.03.003.
|
| [5] |
GATHOGO E, HARBER M, BHAGANI S, et al. Impact of tacrolimus compared with cyclosporin on the incidence of acute allograft rejection in human immunodeficiency virus-positive kidney transplant recipients[J]. Transplantation, 2016, 100(4):871-878. DOI: 10.1097/TP.0000000000000879.
|
| [6] |
HO ET, WONG G, CRAIG JC, et al. Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review[J]. Transplantation, 2013, 95(9):1120-1128. DOI: 10.1097/TP.0b013e318284c15b.
|
| [7] |
OKIMURA K, MAETA K, KOBAYASHI N, et al. Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects[J]. Am J Transplant, 2014, 14(6):1290-1299. DOI: 10.1111/ajt.12678.
|
| [8] |
PARAJULI S, MANDELBROT DA, MUTH B, et al. Rituximab and monitoring strategies for late antibody-mediated rejection after kidney transplantation[J]. Transplant Direct, 2017, 3(12):e227. DOI: 10.1097/TXD.0000000000000746.
|
| [9] |
QUERIDO S, WEIGERT A, ADRAGÃO T, et al. Intravenous immunoglobulin and rituximab in HLA highly sensitized kidney transplant recipients[J]. Transplant Proc, 2018, 50(3):723-727. DOI: 10.1016/j.transproceed.2018.02.016.
|
| [10] |
MASOUD S, MCADOO SP, BEDI R, et al. Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab[J]. Rheumatology (Oxford), 2018. DOI:10.1093/rheumatology/key042 [Epubahead of print].
|
| [11] |
STAHNKE AM, HOLT KM. Ocrelizumab: a new B-cell therapy for relapsing remitting and primary progressive multiple sclerosis[J]. Ann Pharmacother, 2018, 52(5):473-483. DOI: 10.1177/1060028017747635.
|
| [12] |
MARTIN ST, CARDWELL SM, NAILOR MD, et al. Hepatitis B reactivation and rituximab: a new boxed warning and considerations for solid organ transplantation[J]. Am J Transplant, 2014, 14(4):788-796. DOI: 10.1111/ajt.12649.
|
| [13] |
CHAUDHURI A, OZAWA M, EVERLY MJ, et al. The clinical impact of humoral immunity in pediatric renal transplantation[J]. J Am Soc Nephrol, 2013, 24(4):655-664. DOI: 10.1681/ASN.2012070663.
|
| [14] |
ESKANDARY F, REGELE H, BAUMANN L, et al. A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection[J]. J Am Soc Nephrol, 2018, 29(2):591-605. DOI: 10.1681/ASN.2017070818.
|
| [15] |
REQUIAO-MOURA LR, DE SANDES-FREITAS TV, MARCELO-GOMES G, et al. Bortezomib in kidney transplant: current use and perspectives[J]. Curr Drug Metab, 2017, 18(12):1136-1146. DOI: 10.2174/1389200218666171121100716.
|
| [16] |
PICKERING MC, D'AGATI VD, NESTER CM, et al. C3 glomerulopathy: consensus report[J]. Kidney Int, 2013, 84(6):1079-1089. DOI: 10.1038/ki.2013.377.
|
| [17] |
VALENZUELA NM, MCNAMARA JT, REED EF. Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms[J]. Curr Opin Organ Transplant, 2014, 19(1):33-40. DOI: 10.1097/MOT.0000000000000040.
|
| [18] |
STEGALL MD, DIWAN T, RAGHAVAIAH S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients[J]. Am J Transplant, 2011, 11(11):2405-2413. DOI: 10.1111/j.1600-6143.2011.03757.x.
|
| [19] |
WISEMAN AC. Immunosuppressive medications[J]. Clin J Am Soc Nephrol, 2016, 11(2):332-343. DOI: 10.2215/CJN.08570814.
|
| [20] |
VINCENTI F, TEDESCO SILVA H, BUSQUE S, et al. Randomized phase 2b trial of tofacitinib (CP-690, 550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year[J]. Am J Transplant, 2012, 12(9):2446-2456. DOI: 10.1111/j.1600-6143.2012.04127.x.
|
| [21] |
ATLANI M, SHARMA RK, GUPTA A. Basiliximab induction in renal transplantation: long-term outcome[J]. Saudi J Kidney Dis Transpl, 2013, 24(3):473-479. doi: 10.4103/1319-2442.111010
|
| [22] |
GELFAND EW. Intravenous immune globulin in autoimmune and inflammatory diseases[J]. N Engl J Med, 2012, 367(21):2015-2025. DOI: 10.1056/NEJMra1009433.
|
| [23] |
JORDAN SC, TOYODA M, KAHWAJI J, et al. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients[J]. Am J Transplant, 2011, 11(2):196-202. DOI: 10.1111/j.1600-6143.2010.03400.x.
|
| [24] |
YAPRAK M, DOǦRU V, SANHAL CY, et al. Fertility outcome after renal transplantation: a single-center experience[J]. Transplant Proc, 2019, 51(4):1108-1111. DOI: 10.1016/j.transproceed.2019.01.111.
|
| [25] |
ZHENG J, SONG W. Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients: a systematic review and Meta-analysis of randomized controlled trials[J]. Medicine (Baltimore), 2017, 96(28):e7151. DOI: 10.1097/MD.0000000000007151.
|
| [26] |
YANG A, WANG B. Sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids: focus on acute rejection, patient and graft survival[J]. Am J Ther, 2015, 22(2):98-104. DOI: 10.1097/MJT.0b013e31827ab584.
|
| [27] |
TAYLOR EB, RYAN MJ. Immunosuppression with mycophenolate mofetil attenuates hypertension in an experimental model of autoimmune disease[J]. J Am Heart Assoc, 2017, 6(3): e005394. DOI: 10.1161/JAHA.116.005394.
|
| [28] |
于立新, 周敏捷, 罗敏.肾移植受者应用霉酚酸酯的合理治疗窗[J].南方医科大学学报, 2014, (12):1842-1845. DOI: 10.3969/j.issn.1673-4254.2014.12.29.
YU LX, ZHOU MJ, LUO M. Therapeutic window of mycophenolate mofetil for preventing acute graft rejection following renal transplantation[J].J South Med Univ, 2014, 34(12):1842-1845. DOI: 10.3969/j.issn.1673-4254.2014.12.29.
|
| [29] |
JAW J, HILL P, GOODMAN D. Combination of leflunomide and everolimus for treatment of BK virus nephropathy[J]. Nephrology (Carlton), 2017, 22(4):326-329. DOI: 10.1111/nep.12948.
|
| [30] |
周异群.心脏死亡器官捐献肾移植术后肾功能延迟恢复的免疫抑制剂选择[J].复旦学报(医学版), 2018, 45(2):240-244.DOI: 10.3969/j.issn.1672-8467.2018.02.015.
ZHOU YQ. Immunosuppressant treatment for delayed graft function in renal transplantion of donation after cardiac death[J]. J Fudan Univ (Med Sci), 2018, 45(2):240-244. DOI: 10.3969/j.issn.1672-8467.2018.02.015.
|
| [31] |
黄俊, 李剑文, 梁鸣, 等.他克莫司联合激素治疗血清抗PLA2R抗体持续高滴度的难治性特发性膜性肾病[J].实用医学杂志, 2018, 34(8):1355-1359. DOI: 10.3969/j.issn.1006-5725.2018.08.033.
HUANG J, LI JW, LIANG M, et al. Tacrolimus combined with prednisone for treatment of refractory idiopathic membranous nephropathy with persistent high serum anti-phospholipase A2 receptor antibody titers[J]. J Pract Med, 2018, 34(8):1355-1359. DOI: 10.3969/j.issn.1006-5725.2018.08.033
|
WeChat Subscription Account
Wechat Service Account
Supported by:
Beijing Renhe Information Technology Co. Ltd
DownLoad: